Literature DB >> 17273694

[Intravitreal triamcinolone injection in the treatment of idiopathic juxtafoveal telangiectasis].

Otacílio Oliveira Maia1, Walter Yukihiko Takahashi, Maria Teresa Brizzi C Bonanomi, Vinícius Paganini Nascimento, Carlos Sérgio Nascimento de Melo.   

Abstract

Case report of one idiopathic juxtafoveal telangiectasis (IJT) 1A patient whose right eye was treated with a 4 mg intravitreal triamcinolone acetonide injection. The outcome was evaluated by visual acuity and optic coherence tomography. The visual acuity and the caliper retinal thickness before triamcinolone injection were respectively 20/100 and 569 microm, and 20/60 and 371 microm after three weeks and 20/100 and 614 microm after six week of follow-up. The stabilization of the vascular wall due to the intravitreal triamcinolone injection leads to a transitory improvement in vision and reduction in macular edema in the TJI 1A eyes. No permanent help by the photocoagulation could be shown.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17273694

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  4 in total

1.  Intravitreal triamcinolone for management of idiopathic juxtafoveolar telangiectasis.

Authors:  Nitin Nema; Michael S Ip
Journal:  Oman J Ophthalmol       Date:  2010-01

2.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 3.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

4.  Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.

Authors:  Eric J Sigler; John C Randolph; Jorge I Calzada; Steve Charles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-06       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.